The future of urothelial carcinoma: a 2024-2025 update of early-phase trials of novel therapeutic agents.

PURPOSE OF REVIEW: The treatment landscape for advanced and non-muscle-invasive urothelial carcinoma (UC) is rapidly evolving beyond platinum chemotherapy and immune checkpoint inhibitors. This review is timely and relevant as it synthesizes recent, impactful data from 2024-2025 early-phase trials, highlighting agents poised to redefine clinical standards.

RECENT FINDINGS: Recent studies showcase promising novel strategies. These include next-generation targeted therapies like sapanisertib, novel antibody-drug conjugates (ADCs) and bicycle toxin conjugates (BTCs) such as zelenectide pevedotin (BT8009) and dual-ADC combinations with high response rates, and the approved immunomodulator N-803 for BCG-unresponsive disease. Furthermore, innovative intravesical therapies, including ADCs (disitamab vedotin) and immune checkpoint inhibitors, show transformative potential for localized disease with favorable safety.

SUMMARY: The findings indicate a shift towards more effective and tailored treatments. Future efforts must focus on biomarker validation, strategic sequencing, and managing combination toxicities to integrate these advances into practice and improve patient outcomes.